Dr. Olga Chernoloz, PhD, Chief Scientific Officer, Wake.

Dr Chernoloz will be speaking about Wake’s Psilocybin micro-dosing controlled clinical trial.  This is a first in this area and an very important clinical trial.

Dr Chernoloz is a specialist in neuropsycho-pharmacology with a PhD in neuroscience from the University of Ottawa.  She has held a number of roles in clinical trial management, drug development, biotech, and pharmaceuticals.  Her early work with patients experiencing severe depression inspired her to apply her scientific background to help people achieve mental wellness.  Olga’s primary focus now centres around researching the growing practice of micro dosing psilocybin.